References
- Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. J Clin Oncol 1991; 9: 509-24.
- Cleeland CS. Cancer-related symptoms. Sem Radiat Oncol 2000; 10: 175-90.
- Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9(Suppl 4): 14-27.
- Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Raja Abdullah RSA. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43: 180-6.
- Stoll BA. Natural history, prognosis, and staging of bone metastases. In: Szoll BA, Parboo S, editors. Bone metastases: monitoring and treatment. New York: Raven; 1983. p. 1-20.
- Chow E, Finkelstein JA, Coleman RE. Metastatic cancer to the bone. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. Vol 2. 8th edition. Philadelphia: Wolters Kluver, Lippincott; 2008. p. 2510-22.
- Debevec L, Debeljak A, Eržen J, Kovač V, Kern I. Characterization of lung cancer patients, their actual treatment and survival: experience in Slovenia. Radiol Oncol 2005; 39: 115-21.
- Lote K, Walloe A, Bjersand A. Bone metastasis. Prognosis, diagnosis and treatment. Acta Radiol Oncol 1986; 25: 227-32.
- Rajer M, Kovač V. Malignant spinal cord compression. Radiol Oncol 2008; 42: 23-31.
- Debois JM. TxNxM1. The anatomy and clinic of metastatic cancer. Dordrecht: Kluwer Academic Publishers; 2002.
- Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21: 337-44.
- Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18.
- Strojan P, Debevec M, Kovač V. Superior sulcus tumor (SST): management at the Institute of Oncology in Ljubljana, Slovenia, 1981-1994. Lung cancer 1997; 17: 249-59.
- Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics an impact in patients with cancer pain. Pain 1999; 81: 129-34.
- Zucali R. Radiotherapy of bone lesions. In: Gerattini S, editor. Bone resorption, metastasis, and diphosphonates. New York: Raven; 1985. p. 117-26.
- Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004; 45: 1358-65.
- Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol 2007; 19: 308-14.
- Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA. Evidence-based standards for cancer pain management. J Clin Oncol 2008; 26: 3879-85.
- Hoskin PJ. Opioids in context: relieving the pain of cancer. The role of comprehensive cancer management. Palliat Med 2008; 22: 303-9.
- Vakaet LA, Boterberg T. Pain control by ionizing radiation of bone matastasis. Int J Dev Biol 2004; 48: 599-606.
- Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of randomised trials. Clin Oncol 2003; 15: 345-52.
- Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dosefractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594-605.
- Loblaw DA, Wu JS, Kirkbride P, Panzarella T, Smith K, Aslanidis J, et al. Pain flare in patients with bone metastases after palliative radiotherapy-a nested randomized control trial. Support Care Cancer 2007; 15: 451-5.
- Hird A, Chow E, Zhang L, Wong R, Wu J, Sinclair E, et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers. Int J Radiat Oncol Biol Phys 2009; 75: 193-7.
- Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction shedule over 12 months of patients follow- up. Radiother Oncol 1999; 52: 111-21.
- Foro Arnalot P, Fontanals AV, Galcerán JC, Lynd F, Latiesas XS, de Dios NR, et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol 2008; 89: 150-5.
- Gaze MN, Kelly CG, Kerr GR, Cull A, Cowie VJ, Gregor A, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol 1997; 45: 109-16.
- Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of shortversus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97: 798-804.
- Hirokawa Y, Wadasaki K, Kashiwado K, Kagemoto M, Katsuta S, Honke Y, et al. A multi-institutional prospective randomized study of radiation therapy of bone metastases. Nippon Igaku Hoshasen Gakkai Zasshi 1988; 48: 1425-31.
- Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1992; 23: 74-8.
- Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys 1998; 42: 161-7.
- Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M, et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. Radiother Oncol 2006; 79: 278-84.
- Kirkbride P, Warde PR, Panzarella T, Aslanidis J, McKenzie M, Sun A. A Randomised trial comparing the efficacy of a single radiation fraction with fractionated radiation therapy in the palliation of skeletal metastases. Int J Radiat Oncol Biol Phys 2000; 48(Suppl 3): 185.
- Koswig S, Budach V. Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol 1999; 175: 500-8.
- Mañas A, Casas F, Ciria JP, López C, Sáez J, Palacios A, et al. Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases. Clin Transl Oncol 2008; 10: 281-7.
- Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 1998; 47: 233-40.
- Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986; 6: 247-55.
- Roos DE, Turner SL, O'Brien PC, Smith JG, Spry NA, Burmeister BH, et al, Trans-Tasman Radiation Oncology Group, TROG 96.05. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol 2005; 75: 54-63.
- Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
- Rasmusson B, Vejborg I, Jensen AB, Andersson M, Banning AM, Hoffmann T, et al. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiother Oncol 1995; 34: 179-84.
- Steenland E, Leer JW, van Houwelingen H, Post Wj, van den Hout WB, Kievit J, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999; 52: 101-9.
- Tong D, Gillick, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982; 50: 893-9.
- Chow E, Lutz S, Beyene J. A single fraction for all, or an argument for fractionation tailored to fit the needs of each individual patient with bone metastases. Int J Radiat Biol Phys 2003; 55: 565-7.
- Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasma 2004; 51: 334-40.
- Jeremic B, Shibamoto Y, Igrutovic I. Single 4 Gy reirradiation for painful bone metastasis following single fraction radiotherapy. Radiother Oncol 1999; 52: 123-7.
- Stanković M, Marić D, Ilić M, Veselinović I, Ninković S, Sečen S. Abscess of C1/C2 cervical vertebrae - errors in diagnosis and therapy. Radiol Oncol 2009; 43: 240-6.
- Haddad P, Wong RK, Pond GR, Soban F, Williams D, McLean M, et al. Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review. Clin Oncol (R Coll Radiol) 2005; 17: 430-4.
- van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003; 95: 222-9.
- Pollicino CA, Turner SL, Roos DE, O'Brien PC. Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain. Radiother Oncol 2005; 76: 264-9.
- Salazar OM, Rubin P, Keller B, Scarantino C. Systemic (half-body) radiation therapy: Response and toxicity. Int J Radiat Oncol Biol Phys 1978; 4: 937-50.
- Salazar OM, Sandhu T, da Motta NW, Perez Escutia MA, Lanzos-Gonzales E, Mouelle-Sone A, et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: A randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 2001; 50: 765-75.
- Salazar OM, Rubin P, Hendrickson FR, Komaki R, Poulter C, Newall J, et al. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer 1986; 58: 29-36.
- Salazar OM, daMotta NW, Bridgman SM, Cardiges NM, Slawson RG. Fractionated half-body irradiation for pain palliation in widely metastatic cancers: Comparison with single dose. Int J Radiat Oncol Biol Phys 1996; 36: 49-60.
- Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46: 38-47.
- Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-13.
- Piffanelli A, Dafermou A, Giganti M, Colamussi P, Pizzocaro C, Bestagno M, et al. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group. Q. J Nucl Med 2001; 45: 100-7.
- Roqué M, Martinez MJ, Alonso P, Catal E, Garcia JL, Ferrandiz M. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2003; 4: CD003347.
- Kampen WU, Fischer M. Pain palliation using unsealed radionuclides. Schmerz 2008; 22: 699-705.
- Gkialas I, Iordanidou L, Galanakis I, Giannopoulos S. The use of radioisotopes for palliation of metastatic bone pain. J BUON 2008; 13: 177-83.
- Liberman B, Gianfelice D, Inbar Y, Beck A, Rabin T, Shabshin N, et al. Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. Ann Surg Oncol 2009; 16: 140-6.
- Tseng YY, Lo YL, Chen LH, Lai PL, Yang ST. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of pain induced by metastatic spine tumor. Surg Neurol 2008; 70(Suppl 1): S78-83.
- Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004; 8: 1-176.
- Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-4.
- Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949-54.
- Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211-21.
- Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: 420-32.
- Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42'446, a new potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-51.
- Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
- Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; 3: CD003474.
- Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-44.
- Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27: 92-103.
- Vogt U, Bielawski KP, Bosse U, Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004; 12: 1109-14.
- Journé F, Magné N, Chaboteaux C, Kinnaert E, Bauss F, Body JJ. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis 2006; 23: 135-47.
- Chang JW, Hsieh JJ, Shen YC, Yeh KY, Wang CH, Li YY, Hsu T. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. Cancer Lett 2009; 278: 17-26.